Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07849283
Starting soon Not applicable

Efficacy of Cognitive Behavioral Therapy at Vestibular Migraine

NCT07849283 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Not applicable
Started
2026-11
Last updated
2026-10-07

Condition(s) studied

Cognitive Behavioral Therapy to Medical Treatment on Functional Ability of Patients With Vestibular Migraine

Investigational drug(s) / intervention(s)

•Group A: Patients will receive Medical treatment only: Beta-blockers (Propranolol) , Calcium channel blockersGroup B: Cognitive Behavioral Therapy (CBT) +Medical treatment

•Group A: Patients will receive Medical treatment only: Beta-blockers (Propranolol) , Calcium channel blockers: Group A: Patients will receive Medical treatment only: beta blocker :20 mg twice daily ca channel blocker:5 mg once daily

Group B: Cognitive Behavioral Therapy (CBT) +Medical treatment: Structured CBT program consisting of 6-8 sessions over 8 weeks . Session 1: Psychoeducation about Vestibular Migraine Session 2: Progressive muscle relaxation and mini relaxation Session 3: Increasing pleasant activities and coping with fear Session 4: Cognitive Restructuring Session 5: Trigger management and skill review. Session 6: Impact of thoughts and feelings (stress management and calm statements) Session 7: Skill review and self -monitoring process Session 8: Summery and review (if needed)

Study summary

The management of vestibular migraine is multifaceted and includes both pharmacological and non-pharmacological approaches. Aim of work Evaluate the efficacy of adding Cognitive Behavioral Therapy (CBT) to standardized Medical treatment on improving functional ability of Vestibular Migraine.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 18-60 years. Patients with a confirmed diagnosis of Vestibular Migraine according to ICHD-3 (Not better accounted by another vestibular disorder or another disease) Psychological state: Patients with stable general and psychological condition. Exclusion Criteria: * Age: below 18, above 60 years Other Vestibular Disorders as Ménière's disease, Benign Paroxysmal Positional Vertigo, Vestibular neuritis and Central neurological disorder Systemic or Other Causes Orthostatic hypotension Anxiety/panic disorders Drug-induced dizziness Psychological state: Patients with active psychiatric disorders requiring immediate intervention. Pregnancy, lactating woman and Cognitive impairment patient

Primary outcome measure(s)

  • improving in Functional Ability of patients with vestibular migraine — 1-Baseline and at 3 months post-intervention
    1-DHI score Dizziness Handicap Inventory (DHI) is a 25-item self-assessment scale used to evaluate the self-perceived handicapping effects imposed by dizziness. The total score ranges from 0 to 100, where 0 indicates no handicap and 100 indicates severe handicap.

Trial sites (1)

FacilityCityRegionStatus
Sohag University Sohag Egypt

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07849283 on ClinicalTrials.gov ↗ ← All trials in Egypt